RecruitingPhase 3NCT04704947
Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
Clinical Study Evaluating Selective or Nonselective Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
Sponsor
Sherief Abd-Elsalam
Enrollment
50 participants
Start Date
Oct 1, 2017
Study Type
INTERVENTIONAL
Conditions
Summary
Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis
Eligibility
Min Age: 50 Years
Inclusion Criteria3
- Male \& female osteoporotic patient aged ≥ 50 years
- Hypertensive \& normotensive patients
- BMD T-score ≥ 2.5 or more SD below peak bone mass
Exclusion Criteria4
- Patients on drugs that may improve osteoporosis disease state such as:
- Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.
- Patients on drugs that may worsen osteoporosis disease state such as:
- Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGnonselective beta blocker
nonselective beta blocker
DRUGcardio-selective beta blocker group
cardio-selective beta blocker group
DRUGalendronate sodium
alendronate sodium
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04704947